Washington University SPORE in Pancreatic Cancer

华盛顿大学 SPORE 在胰腺癌中的应用

• 批准号: 10708572
• 负责人: David G DeNardo
• 金额: $ 206.5万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-28 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10708572
• 关键词: Agonist; Basic Science; Bioinformatics; Biometry; California; Cancer Biology; Cancer Center; Cancer Research Project; Clinic; Clinical; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Communities; Development; Diagnosis; Disease; Drug resistance; Ensure; Environment; Ethics; Faculty; Fostering; Funding; Genomics; Goals; ITGAM gene; Image; Immunologics; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infrastructure; Institution; Leadership; Malignant Neoplasms; Malignant neoplasm of pancreas; Mentors; Metabolic; Minority; Mission; Nebraska; North Carolina; Pancreatic Ductal Adenocarcinoma; Patient Participation; Patient-Focused Outcomes; Patients; Pennsylvania; Quality of life; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Specialized Program of Research Excellence; Stress; Testing; Therapeutic Clinical Trial; Therapeutic Trials; Training; Translational Research; Translations; Universities; Washington; bench-to-bedside translation; cancer genomics; cancer type; career; clinical care; clinical practice; design; drug development; gastrointestinal; immune resistance; improved; improved outcome; innovation; inter-institutional; leukemia; medical schools; multidisciplinary; neoantigen vaccine; novel; novel diagnostics; novel strategies; novel therapeutic intervention; patient population; programs; recruit; resistance mechanism; translational applications; translational cancer research; translational impact; translational potential; treatment strategy

PROJECT SUMMARY The Washington University Specialized Program of Research Excellence (SPORE) in Pancreatic Cancer is a highly translational cancer research program focused entirely on the deadliest form of the disease, pancreatic ductal adenocarcinoma (PDAC). Our outstanding investigators have complementary expertise in basic and clinical studies, and our teams leverage individual expertise in immunology, cancer biology, drug development, genomics, and clinical care to develop novel diagnostic and therapeutic approaches for PDAC. This SPORE application includes three research projects, an administrative core (Core A), two shared- resource cores [Biospecimen Core (Core B) and Biostatistics and Bioinformatics Core (Core C)], and developmental research (DRP) and career enhancement (CEP) programs. In collaboration with our External (EAB) and Internal (IAB) Advisory Boards, we intentionally selected projects with the greatest potential to impact the outcome for patients with PDAC. Basic research at WUSM and UPenn has led to the development of the following three research projects, all of which feature innovative investigator-initiated therapeutic trials for PDAC. All projects deemed to have the most potential for translational impact and share an immunologic theme in their approach. This immunologic theme leverages institutional strengths and highlights our team’s expertise and leadership in this field. Thus far, the immunologic and metabolic therapies that have been increasingly successful for controlling other cancer types have not been impactful in PDAC. Our project leaders have made noteworthy contributions to elucidate the mechanisms underlying this immunologic resistance and drug resistance in PDAC and developed several exciting strategies with potential to overcome these obstacles. The three projects in this application are designed to have significant potential to change clinical practice within 5 years. Project 1. Employing CD11b-agonists to render PDAC responsive to immunotherapy Project 2. Mechanisms of Resistance to Neoantigen Vaccines in PDAC Project 3. Targeting Stress-induced MK2 as Novel Strategy in Pancreatic Cancer Our long-term goals are to improve the survival and the quality of life of patients diagnosed with PDAC. To achieve this goal, we will promote institutional and inter-institutional collaborative research, with an emphasis on translation. We anticipate that no singular approach will solve PDAC and fully commit to supporting the development of novel research concepts as well as highly promising young investigators. Our SPORE will provide access to pancreatic cancer–specific resources to facilitate this mission.

项目摘要 华盛顿大学胰腺癌研究卓越研究专业计划（Spore）是一个 高度翻译的癌症研究计划完全集中在疾病的最致命形式上 导管腺癌（PDAC）。我们杰出的调查员在基本和 临床研究，我们的团队在免疫学，癌症生物学，药物开发方面利用个人专业知识， 基因组学和临床护理，以开发PDAC的新型诊断和治疗方法。 该孢子应用程序包括三个研究项目，一个行政核心（核心A），两个共享 - 资源核心[Bispecemen Core（核心B），生物统计学和生物信息学核心（Core C）]，并且 发展研究（DRP）和职业增强（CEP）计划。与我们的外部合作 （EAB）和内部（IAB）咨询委员会，我们故意选择具有影响最大的项目 PDAC患者的结果。 WUSM和Upenn的基础研究导致了 在三个研究项目之后，所有这些项目都采用了创新的研究人员对PDAC进行的治疗试验。 所有被认为具有最大潜力翻译影响的项目，并在他们的 方法。这种免疫学主题利用机构的优势，突出了我们团队的专业知识和 在这个领域的领导。远处是越来越成功的免疫学和代谢疗法 用于控制其他癌症类型的PDAC没有影响。我们的项目负责人提出了值得注意的 阐明PDAC中这种免疫耐药性和耐药性的基础机制的贡献 并制定了几种令人兴奋的策略，具有克服这些障碍的潜力。这三个项目 应用旨在在5年内具有重大潜力来改变临床实践。 项目1。雇用CD11b激动剂来使PDAC对免疫疗法有反应 项目2。PDAC中对新抗原疫苗的抗性机制 项目3。靶向应力诱导的MK2作为胰腺癌的新策略 我们的长期目标是改善被诊断为PDAC的患者的生存和生活质量。到 实现这一目标，我们将促进机构和机构间合作研究，重点 翻译。我们预计没有单一的方法将解决PDAC并完全致力于支持 发展新颖的研究概念以及高度有前途的年轻研究者。我们的孢子会 提供胰腺癌特定资源的访问权限，以促进这项任务。